1. Home
  2. TXO vs ESPR Comparison

TXO vs ESPR Comparison

Compare TXO & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TXO Partners L.P.

TXO

TXO Partners L.P.

HOLD

Current Price

$11.46

Market Cap

691.6M

Sector

Energy

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXO
ESPR
Founded
2012
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
691.6M
731.9M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
TXO
ESPR
Price
$11.46
$2.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$20.50
$8.75
AVG Volume (30 Days)
207.1K
6.5M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
14.47%
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
$401,012,000.00
$403,135,000.00
Revenue This Year
$17.21
N/A
Revenue Next Year
N/A
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
41.80
21.31
52 Week Low
$10.12
$0.73
52 Week High
$17.90
$4.18

Technical Indicators

Market Signals
Indicator
TXO
ESPR
Relative Strength Index (RSI) 30.50 32.79
Support Level N/A $1.02
Resistance Level $13.05 $2.08
Average True Range (ATR) 0.44 0.20
MACD -0.13 -0.03
Stochastic Oscillator 11.28 3.34

Price Performance

Historical Comparison
TXO
ESPR

About TXO TXO Partners L.P.

TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: